Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Europe close: Stocks take a breather

(Sharecast News) - European stocks were mixed on Wednesday, as investors paused for breath following the best daily performance in nearly a year.during the previous session. The Europe Stoxx 600 Index was up 0.15% at 453.16, having surged 1.97% on Tuesday on the back of easing bond yields in the US, even as hopes rose of further stimulus in China.

Markets were higher in Frankfurt, Madrid and Milan, but lower in Paris, with the latter registering heavy losses on the back of weakness in the luxury sector.

In economic news on Wednesday, German inflation fell to its lowest level since the start of the war in Ukraine.

The annual change in the consumer price index stood at +4.5% in September, down from +6.1% in August and +6.2% in July. Energy prices rose just 1% year-on-year, slowing from the 8.3% growth seen the previous month.

LVMH leads luxury stocks lower

LVMH dropped 7% after the luxury group said organic revenue growth had eased to 9% in the third quarter, well below the 11.2% growth expected by analysts. Sales in the wines and spirits division, in particular, plunged 14%, causing shares in fellow drinks company Pernod Ricard to fall.

"While luxury has been a strong sector lately, given that customers with high disposable incomes are relatively sheltered from cost-of-living pressures, results from LVMH, the first in the sector, appears to suggest that the blockbuster period for luxury is starting to fade," said Victoria Scholar, head of investment at Interactive Investor.

Others in the sector, such as Kering and Hermes, also took a hit in Paris trading.

On the other hand, Danish pharma giant Novo Nordisk rose strongly after calling an end to a trial of its Ozempic drug after early signs of success. The trial, studying Ozempic's treatment of kidney failure in diabetes patients, was supposed to continue for nearly a year longer.

Share this article

Related Sharecast Articles

US pre-open: Dow futures little changed ahead of FOMC meeting
(Sharecast News) - Dow Jones futures were little changed ahead of the bell on Tuesday as market participants looked ahead to the outcome of the Federal Reserve's two-day policy meeting and more mega-cap earnings.
London midday: FTSE pushes higher as HSBC, Whitbread gain
(Sharecast News) - London stocks had extended gains by midday on Tuesday, helped along by solid performances from the likes of HSBC and Whitbread, as investors eyed the start of the Federal Reserve's two-day policy meeting.
Asia report: Most markets rise as yen falls back
(Sharecast News) - Asian markets saw a mixed day of trading on Tuesday, as investors navigated between positive cues from Wall Street and cautious sentiment surrounding China's factory activity.
Asia report: Most markets rise as yen falls back
(Sharecast News) - Asian markets saw a mixed day of trading on Tuesday, as investors navigated between positive cues from Wall Street and cautious sentiment surrounding China's factory activity.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.